We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Familial Genetics Influence Migraine Type

By LabMedica International staff writers
Posted on 16 May 2018
Familial aggregation in chronic diseases is well known but its background is not well understood. More...
Migraine is an example of a common disease that can aggregate in families. It is one of the most common brain disorders worldwide, affecting approximately 15% to 20% of the adult population in developed countries.

The polygenic nature of migraine is well documented by genome-wide association studies (GWAS) that have identified over 40 loci associated to common forms of migraine. The familial aggregation could be explained by rare, penetrant variants that segregate according to Mendelian inheritance or by the sufficient polygenic accumulation of common variants, each with an individually small effect, or a combination of the two hypotheses. Three genes (CACNA1A, ATP1A2 and SCN1A) are associated to hemiplegic migraine, a severe form of migraine that induces stroke-like symptoms. These genes fall under a Mendelian inheritance model, meaning the two copies of a gene a child inherits from his or her parents determine a trait or disease.

A large group of scientist working with the Institute for Molecular Medicine (Helsinki, Finland) developed a polygenic risk score to estimate the genetic burden of common variants. In all, hundreds (possibly even thousands) of loci linked to migraines were incorporated into the polygenic risk score. The collaborators then tested the influence of the polygenic risk score and the three known Mendelian migraine-linked genes within a large family study of migraine sufferers in Finland. The study included medical history and genetic data of 1,589 families (made up of 8,319 individuals) of known migraine sufferers. The family migraine cohort was compared against other large cohorts as a control, such as the FINRISK study that had 14,470 people total, including 1,101 people with migraine. Genotyping was performed in seven batches on either the Illumina CoreExome or Illumina PsychArray, which share the Infinium HumanCore backbone including 480,000 variants in common.

The scientists found that all their results showed that the polygenic common variants were driving migraine risk more than the three Mendelian genes. If a person's migraines started at an earlier age, if a person experienced more severe migraines, or if migraines ran in a person's family, the data showed that it's more likely that person had a greater genetic burden of common polygenic variants to blame. On the other hand, the three rare but powerful Mendelian genes linked to migraine did not seem to influence migraine risk as much as the scientists expected. Out of the large family study, they identified 45 families with hemiplegic migraine and sequenced their genes. Migraines in only four out of 45 families were driven by the rare Mendelian genes but more cases were driven by common variants.

The authors concluded that the hypothesis that migraine subtypes are genetically heterogeneous diseases and that regardless of whether they are common (i.e., migraine without aura (MO) and migraine with typical aura) or rare (i.e., familial (FHM) and sporadic (SHM) subtypes, common polygenic variation significantly contributes to the aggregation of the disease in families. Aarno Palotie, MD, PhD, the senior author of the study, said, “The strength of the common variants in these families surprised us. This really shows, in a very big sample set, that common variants are very important factors in aggregation of migraines in the family.” The study was published on May, 3, 2018, in the journal Neuron.

Related Links:
Institute for Molecular Medicine


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.